"Quinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011804
|
| MeSH Number(s) |
D03.633.100.810
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinolines".
Below are MeSH descriptors whose meaning is more specific than "Quinolines".
This graph shows the total number of publications written about "Quinolines" by people in this website by year, and whether "Quinolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 4 | 0 | 4 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 4 | 2 | 6 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 4 | 5 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 4 | 0 | 4 |
| 2018 | 4 | 0 | 4 |
| 2019 | 2 | 3 | 5 |
| 2020 | 1 | 2 | 3 |
| 2021 | 5 | 2 | 7 |
| 2022 | 1 | 3 | 4 |
| 2023 | 2 | 0 | 2 |
| 2024 | 3 | 2 | 5 |
| 2025 | 7 | 3 | 10 |
| 2026 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinolines" by people in Profiles.
-
Comparative adjuvant therapy to reduce vancomycin-associated nephrotoxicity in an animal model. Antimicrob Agents Chemother. 2026 Oct 07; 70(10):e0088726.
-
Management Strategies for Hepatotoxicity Associated With Elexacaftor/Tezacaftor/Ivacaftor: Results of a Provider Survey. Pediatr Pulmonol. 2026 Aug; 61(8):e71778.
-
Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation. Clin Pharmacokinet. 2026 Sep; 65(9):1389-1403.
-
Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases. Breast. 2026 Oct; 89:104881.
-
Inhibitory effect of the water-soluble retinoid X receptor partial agonist CAt-PMN on allergic conjunctivitis-like responses in mice. Exp Eye Res. 2026 Sep; 270:111131.
-
A 2-year randomized trial of pitavastatin calcium vs placebo to treat combined dyslipidemia in adolescents with overweight and obesity. J Clin Lipidol. 2026 Jun; 20(6):1212-1235.
-
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. Leukemia. 2026 02; 40(2):304-313.
-
A multicenter trial to test pitavastatin calcium in youth with combined dyslipidemia of obesity: Design, implementation, challenges, and responses. Am Heart J. 2026 Apr; 294:107327.
-
Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2026 03; 21(3):103505.